January 2026
Addiction
What January 2026's 10 new studies found, synthesized from the papers below. All Addiction research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Addiction, substance use disorder, dependence, alcohol use disorder, opioid use disorder, then ranked by relevance.
Research published in January 2026 indicates that psychedelics such as psilocybin, MDMA, LSD, and ayahuasca show promise for treating substance use disorders, often in conjunction with psychotherapy, though methodological concerns and safety risks remain. Evidence from reviews and observational studies is generally consistent in suggesting symptom reduction, but the field is limited by small samples, open-label designs, and potential risks such as drug interactions and the framing of ibogaine as an alternative to standard opioid use disorder medications. The main caveat is that most findings come from narrative reviews and observational data rather than large, controlled trials, and durability of effects beyond six months is not well established.
Confidence in the evidence
Low-Moderate- Multiple narrative and systematic reviews (article_ids 27882, 18109, 30125) converge on positive signals for psychedelics in substance use disorders, but these are syntheses of existing literature, not new primary trials.
- One longitudinal observational study (article_id 28363) with 280 participants shows sustained benefits for up to 180 days, but lacks a control group and blinding.
- A qualitative analysis (article_id 18731) identifies a potential mechanism (inner dialogue) in a small sample, but generalizability is limited.
- Safety concerns are highlighted: ibogaine may pose risks if used to replace standard medications (article_id 19475), and MAOIs have documented interactions with psychoactive substances (article_id 19463).
- No large-scale, double-blind, placebo-controlled RCTs specifically on addiction were reported in this January 2026 set.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelics in psychiatric treatment: a literature review 2026 | literature review | Supports | Psilocybin demonstrated benefits in substance use disorders, and LSD showed promising effects in substance use disorders. | |
| THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS 2026 | systematic review | Supports | Contemporary clinical trials demonstrate significant therapeutic potential of psilocybin and LSD in substance use disorders. | |
| Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms 2026 | qualitative | Supports | Responders to psilocybin-assisted psychotherapy were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory descriptions and suppressive coping. | |
| Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data. 2026 | narrative review | 219 | Mixed | MAOIs have potential drug interactions with psychoactive substances (e.g., serotonin toxicity with MDMA, hypertensive urgency with alcohol), and the literature on using MAOIs to treat SUDs is scant. |
| Ibogaine for Opioid Use Disorder: An Unrecognized Risk. 2026 | commentary | Opposes | Ibogaine for opioid use disorder may pose an unrecognized risk if used to replace standard mortality-reducing medications like methadone or buprenorphine, potentially increasing overdose risk. | |
| Sleep alterations in substance use disorders: a systematic review and meta-analysis. 2026 | systematic review and meta-analysis | 7500 | Opposes | Sleep disturbances (reduced total sleep time, slow-wave sleep, and poorer sleep quality) are common across multiple substance use disorders, persisting beyond initial abstinence. |
| Partydrogen im Überblick 2026 | review | Unclear | Party drugs (including alcohol, cannabis, MDMA, ketamine, psychedelics) have diverse pharmacological mechanisms and are associated with polydrug use, but the review does not directly address addiction treatment outcomes. | |
| Psychedelics for the Treatment of Substance Use Disorders: A Narrative Review of the Literature. 2026 | narrative review | Supports | Population surveys, observational studies, and clinical trials suggest that psychedelics are associated with symptom reduction in substance use disorders, though methodological concerns limit validity and generalizability. | |
| Possible Effects of MDMA on Vehicle Driving Competencies 2026 | experimental | Opposes | Simulated visual disruption from MDMA negatively affected spatial orientation and led to more collisions and longer completion times on a driving course. | |
| The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study. 2026 | longitudinal observational | 280 | Supports | Ritualistic ayahuasca use combined with psychotherapeutic support was associated with significant reduction in depression scores sustained for up to 180 days, with potential benefits for substance dependence. |
Psilocybin demonstrated benefits in substance use disorders, and LSD showed promising effects in substance use disorders.
literature review
Contemporary clinical trials demonstrate significant therapeutic potential of psilocybin and LSD in substance use disorders.
systematic review
Responders to psilocybin-assisted psychotherapy were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory descriptions and suppressive coping.
qualitative
MAOIs have potential drug interactions with psychoactive substances (e.g., serotonin toxicity with MDMA, hypertensive urgency with alcohol), and the literature on using MAOIs to treat SUDs is scant.
narrative review Sample size: 219
Ibogaine for opioid use disorder may pose an unrecognized risk if used to replace standard mortality-reducing medications like methadone or buprenorphine, potentially increasing overdose risk.
commentary
Sleep disturbances (reduced total sleep time, slow-wave sleep, and poorer sleep quality) are common across multiple substance use disorders, persisting beyond initial abstinence.
systematic review and meta-analysis Sample size: 7500
Party drugs (including alcohol, cannabis, MDMA, ketamine, psychedelics) have diverse pharmacological mechanisms and are associated with polydrug use, but the review does not directly address addiction treatment outcomes.
review
Population surveys, observational studies, and clinical trials suggest that psychedelics are associated with symptom reduction in substance use disorders, though methodological concerns limit validity and generalizability.
narrative review
Simulated visual disruption from MDMA negatively affected spatial orientation and led to more collisions and longer completion times on a driving course.
experimental
Ritualistic ayahuasca use combined with psychotherapeutic support was associated with significant reduction in depression scores sustained for up to 180 days, with potential benefits for substance dependence.
longitudinal observational Sample size: 280
Points of agreement
- Multiple reviews (27882, 18109, 30125) converge on the finding that psychedelics (psilocybin, LSD, MDMA, ayahuasca) show therapeutic potential for substance use disorders.
- The importance of psychotherapeutic support and integration is highlighted across studies (18731, 28363, 30125).
- Safety concerns regarding drug interactions and risks are noted in multiple studies (19463, 19475).
Conflicts
- Ibogaine is framed as a potential risk if used to replace standard OUD medications (19475), while other psychedelics are generally presented as promising adjuncts (27882, 18109, 30125).
- The MAOI review (19463) emphasizes potential harms from drug interactions, whereas psychedelic reviews (27882, 18109) focus on therapeutic benefits with less emphasis on such interactions.
Gaps
- Durability of effects beyond six months is not established (only 180-day follow-up in 28363).
- Large-scale, double-blind, placebo-controlled RCTs specifically for addiction are absent from this set.
- Safety and efficacy in vulnerable populations (e.g., those with polysubstance use, comorbidities) are understudied.
- The role of specific psychotherapeutic frameworks and integration processes needs further systematic investigation.